Adocia shares break through their €4.38 resistance level, top of the Paris market
The Lyon-based biotech posts the largest gain on the Paris market at midday. The move extends a rebound under way since the start of the week, on the eve of a scientific event in Washington.
A resistance level broken, an RSI at 80 after a week of strong gains
The stock trades at €4.93 and gains 14.54% over the session. It broke intraday through its €4.38 resistance, the highest of the last 30 sessions, which has now become support. This gain adds to a 72.13% rise over one week, so the price now stands well above its moving averages: the gap reaches 61.11% with the MM20, 65.44% with the MM50 and 12.81% with the MM200.
The RSI at 80 signals an overbought configuration. The next resistance is at €5.72. Over one year, the stock remains down 45.64%, a reminder of the scale of the progress made since recent lows.
A poster on AdoXLong at ObesityWeek and cash runway extended to Q1 2028
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Adocia will present new in vivo results on its AdoXLong platform at ObesityWeek, held in Washington from November 14 to 17, in the form of a poster on November 14. This technology, still at the preclinical stage, aims for a monthly injection. On the financing side, the €8.4 million cash position as of September 30 and the €7 million transaction announced on October 20 extend the financing horizon to the first quarter of 2028.
When it published its nine-month results on October 29, 2026, the company cited among its main risks its dependence on a $20 million milestone payment, conditional on the marketing authorization of BioChaperone Lispro in China. Saturday's poster is the company's next scheduled event.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
